CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 11,288 enrolled
Drug / intervention
Leuprorelin acetatedrug
Likely dose
Leuprorelin acetate 11.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02167893
NCT02167893N/ACompleted
CompareCT.gov

Leuprorelin Acetate SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"

Takeda·observational·Posted Jun 19, 2014·Updated Mar 29, 2017

In Brief

An observational study evaluating Leuprorelin acetate for Prostate Cancer. Completed, enrolled 11,288 participants.

Detailed Summary

The purpose of this survey is designed to evaluate the efficacy and safety of long-term use (96 weeks) of leuprorelin acetate SR 11.25 milligram (mg) injection kit (Leuplin SR 11.25 mg injection kit) in prostate cancer participants in daily medical practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 19, 2014
Enrollment StartOct 1, 2005
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 12.0 years ago

Interventions

Leuprorelin acetatedrug

Leuprorelin acetate SR 11.25 mg injection kit